In this GEN Market & Tech Analysis report we examine the landscape of cancer personalized medicine based on the results of bottom-up market analyses, which pinpoint the current status and trajectory of cancer personalized medicine.

Highlights of this report:

  • Cancer personalized medicine is the major driver moving the entity of personalized medicine and patient-disease management forward.
  • 70% of the total efforts in the personalized medicine space are focused on the various cancer segments taken together.
  • The impact of microRNAs, epigenetics, and other novel biomarker classes on the cancer personalized medicine space is small currently—indeed the majority of biomarkers are gene- and protein expression-based.
  • The impact of companion diagnostics and tailored therapeutics development is expected to expand the reach of personalized medicine beyond cancer into other disease classes.
  • The collision of NGS into cancer personalized medicine has begun.

Click here to access this article


Also of Interest

This site uses Akismet to reduce spam. Learn how your comment data is processed.